



NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN USA, AUSTRALIA, CANADA, HONG KONG OR JAPAN.

**Press release**

**Stockholm, 21 July 2014**

## Notice of price stabilization in Bactiguard Holding

Swedbank AB (publ) ("Swedbank") has exercised the possibility to, in connection with the initial public offering ("IPO") of Bactiguard Holding AB (publ) ("Bactiguard" or the "Company"), exercise price stabilization transactions.

The stabilization period commenced on June 19, 2014 and ended on July 18, 2014. All stabilization transactions were carried out in the interval of SEK 28.55 to SEK 37.85. The stabilization period has now ended and no further stabilization transactions will be exercised.

Date	Price
June 19, 2014	37.85
June 23, 2014	32.28
June 24, 2014	33.40
June 25, 2014	33.00
June 26, 2014	32.80
June 30, 2014	33.90
July 2, 2014	33.16
July 3, 2014	31.87
July 4, 2014	30.33
July 15, 2014	29.54
July 16, 2014	29.50
July 17, 2014	28.55

The 1,638,336 B-shares in Bactiguard that Swedbank borrowed from Bactiguard B.V. and KK Invest AB, Bactiguard's main owners, with the purpose to cover the over-allotment in the IPO have been returned. As a result of the return of the B-shares, the main owners will file disclosure notifications.

Swedbank has acted as Lead Manager and Sole Bookrunner and ABG Sundal Collier has acted as Co-Lead Manager in connection with the IPO. Cederquist is legal advisor and Lenner & Partners is financial advisor to the Company.

*This is information that Bactiguard Holding AB (publ) is required to publish in compliance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on July 21, 2014 at 07.30 am.*

**For further information please contact:**

Fredrik Järsten, CFO, mobile: +46 725 500 089



*NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN USA, AUSTRALIA, CANADA, HONG KONG OR JAPAN.*

### **About Bactiguard**

Bactiguard is a Swedish medtech company with a business concept of preventing healthcare-related infections, reducing the use of antibiotics and saving lives by developing and supplying infection prevention solutions for the healthcare industry. The company's patented coating prevents healthcare-associated infections by reducing bacterial adhesion and growth on medical devices. Bactiguard®-coated urinary catheters are market leading in the US and Japan, and in recent years the company has developed its own product portfolio of coated catheters for the urinary and respiratory tract and the blood stream. Bactiguard is currently in a strong expansion phase, focused on new markets in the EU, Middle East, Asia and South America. The company reported sales of approximately SEK 130 million in 2013 and has 60 employees, headquarters in Stockholm and production facilities in Markaryd and Malaysia. The Bactiguard share is listed on NASDAQ OMX Stockholm. Read more at [www.bactiguard.se](http://www.bactiguard.se).